Page 8 - Aser Surgery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.

Adopting an infinite mindset could be the antidote to the slow destruction of healthcare by short-term thinking.

A Janux Therapeutics T cell engager has early clinical data showing improvement in cases of advanced prostate cancer, validating the technology platform that produced the therapy. Janux is now leveraging its soaring stock price to raise $175 million in a stock offering.

In the venture capital community, there’s a bit of a debate about what matters more to digital health investors in today's fundraising environment — growth or profitability. Cathy Gao, a partner at Sapphire Ventures, thinks VCs are still putting a premium on growth, but she noted that the conversation is very nuanced.

The FMT era has been productive, but now it’s time to rally together as an industry to accelerate next-generation LBP drug discovery, development and FDA approval.